Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)

BIOLOGICAL2 trials

Sponsors

Sanofi, Sanofi Pasteur, a Sanofi Company

Conditions

Healthy VolunteersMeningococcal ImmunisationMeningococcal Immunisation (Healthy Volunteers)

Phase 3

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

CompletedNCT04368429

SanofiMeningococcal Immunisation (Healthy Volunteers)

Start: 2020-05-22End: 2020-11-07Updated: 2025-09-15

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

CompletedNCT04490018

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers, Meningococcal Immunisation

Start: 2021-03-16End: 2022-05-11Updated: 2025-09-12

Related Papers

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study

Infectious Diseases and Therapy2024-07-026 citations

1139. Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Compared to a Meningococcal Reference Vaccine (MCV4-TT) in Healthy Adolescents

Open Forum Infectious Diseases2023-11-271 citations

Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2–55 Years) in Japan: a Phase III Randomized Study

Japanese Journal of Infectious Diseases2023-01-301 citations

04. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Meningococcal Vaccine-Naive Participants Across a Broad Age Range (2-55 Years) in Japan

Open Forum Infectious Diseases2021-11-01